After announcing it would start selling its assets earlier this year, along with laying off nearly half the company, the ...

Ultragenyx is gearing up to take its glycogen storage disease (GSD) treatment to regulators next year after the gene therapy ...

Baxter put forward clinical data showing that its expanded hemodialysis approach, which aims to filter out a greater range of ...

Immunovant’s decision to prioritize a next-gen FcRn antibody over phase 3 myasthenia gravis (MG) prospect batoclimab means ...

Soterios Pharma is eyeing phase 3 after a 1% dose of the company's alopecia areata cream improved severity of the condition, ...

The new guidance explains that once a sponsor receives an abbreviated new drug application (ANDA), new drug application (NDA) ...

CAR-T cell therapy has been the darling of the oncology world for more than a decade, where it’s had most success against ...